
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 6 |
| miRNA | 1 |
| Chemical drugs | 1 |
| Recombinant polypeptide | 1 |
| CIK therapy | 1 |
Target |
Mechanism CDC20 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date28 Feb 2023 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Feb 2026 |
Sponsor / Collaborator |
Start Date01 Jan 2026 |
Sponsor / Collaborator |
Start Date29 Dec 2025 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
miR-195 | Ischemic stroke More | Preclinical |
Indoxyl sulfate | Chronic Kidney Diseases More | Preclinical |
Pro-Urelumab ( 4-1BB ) | Neoplasms More | Preclinical |
PDI inhibitor 14d (Taipei Medical University) ( PDI ) | Thrombosis More | Preclinical |
CIK cell therapy(Kaohsiung Medical University) | Triple Negative Breast Cancer More | Preclinical |





